• 1639 Citations
  • 19 h-Index

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Hiroyuki Yasuda is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 6 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

  • 1639 Citations
  • 19 h-Index
  • 63 Article
  • 1 Comment/debate
  • 1 Editorial
  • 1 Review article

IGF2 Autocrine-mediated IGF1R activation is a clinically relevant mechanism of osimertinib resistance in Lung Cancer

Manabe, T., Yasuda, H., Terai, H., Kagiwa, H. D. A., Hamamoto, J., Ebisudani, T., Kobayashi, K., Masuzawa, K., Ikemura, S., Kawa, I. D. A., Hayashi, Y., Fukui, K., Horimoto, K., Fukunaga, K. & Soeji, K. M. A., 2020 Apr 1, In : Molecular Cancer Research. 18, 4, p. 549-559 11 p.

Research output: Contribution to journalArticle

Open Access
  • Targeting Co-Occurring Genomic Alterations in MET Exon 14 Skipping Mutation-Positive NSCLC

    Yasuda, H., 2020 May, In : Journal of Thoracic Oncology. 15, 5, p. 679-680 2 p.

    Research output: Contribution to journalEditorial

    A phase II trial of induction of erlotinib followed by cytotoxic chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer patients

    Tani, T., Naoki, K., Yasuda, H., Arai, D., Ishioka, K., Ohgino, K., Yoda, S., Nakayama, S., Satomi, R., Terai, H., Ikemura, S., Sato, T. & Soejima, K., 2019 Nov 1, In : Cancer Chemotherapy and Pharmacology. 84, 5, p. 1065-1071 7 p.

    Research output: Contribution to journalArticle

  • 2 Citations (Scopus)

    Effect of FGF/FGFR pathway blocking on lung adenocarcinoma and its cancer-associated fibroblasts

    Hegab, A. E., Ozaki, M., Kameyama, N., Gao, J., Kagawa, S., Yasuda, H., Soejima, K., Yin, Y., Guzy, R. D., Nakamura, Y., Ornitz, D. M. & Betsuyaku, T., 2019 Oct 1, In : Journal of Pathology. 249, 2, p. 193-205 13 p.

    Research output: Contribution to journalArticle

  • 2 Citations (Scopus)

    Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations

    Hasegawa, H., Yasuda, H., Hamamoto, J., Masuzawa, K., Tani, T., Nukaga, S., Hirano, T., Kobayashi, K., Manabe, T., Terai, H., Ikemura, S., Kawada, I., Naoki, K. & Soejima, K., 2019 Jan 1, In : Lung Cancer. 127, p. 146-152 7 p.

    Research output: Contribution to journalArticle

  • 8 Citations (Scopus)